
## Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis


## **Supplementary Materials and Methods**

## **Tumor xenografts**

For the subcutaneous tumor model, animals were inoculated by a subcutaneous (s.c.) injection with U87 cells ( $5 \times 10^6$  cells in PBS). Animals were randomly assigned to various groups and treated with fluoxetine (10 mg/kg/day, o.p.) or temozolomide (TMZ) (5 mg/kg/day, intraperitoneally (i.p.)) when the tumor had reached an average size of  $100 \text{ mm}^3$ . Tumor sizes were measured with external calipers, and the volume was calculated as the (length/2) × (width)<sup>2</sup>.



Supplementary Fig. 1: Fluoxetine suppressed the growth of glioblastoma cells in vivo. The effect of fluoxetine or temozolomide (TMZ) on tumor growth in vivo. The results were statistically analyzed by two-way Repeated Measured ANOVA. The differences among control, Fluoxetine, and TMZ on tumor size at certain days were evaluated using Bonferroni post hoc analysis.  $^{***}p$ <0.001 when compared with the control group.



Supplementary Fig. 2: Fluoxetine specifically elevated the intracellular calcium concentration in AMPAR-expressing glioblastoma cell lines. Fluorescence imaging of  $[Ca^{2+}]_i$  using Fluo-3 was conducted before and after 30  $\mu$ M fluoxetine treatment. Summary histograms of Fluo-3 intensity were shown. A marked increase in the fluorescence intensity was seen in cells exposed to fluoxetine compared to the control (treatment at 0 min). The results were statistically analyzed by Student's t-test. \*\*\*p<0.001 when compared with the control (treatment at 0 min).